How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/staphylococcus-aureus-bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Staphylococcus Aureus Bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Staphylococcus Aureus Bronchitis (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Staphylococcus Aureus Bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Methocillin S	CLOXACILLIN	GSK	cloxacillin		1974-01-01
Bactocill In Plastic Container	OXACILLIN	Apothecon		Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1971-01-01
Pathocil	DICLOXACILLIN	Pfizer	Penicillin-class Antibacterial	Muscarinic acetylcholine receptor M1	1968-01-01
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Staphylococcus Aureus Bronchitis
Pfizer · 2 drugs in Staphylococcus Aureus Bronchitis
Apothecon · 1 drug in Staphylococcus Aureus Bronchitis
Assistance Publique - Hôpitaux de Paris · 1 drug in Staphylococcus Aureus Bronchitis
GSK · 1 drug in Staphylococcus Aureus Bronchitis
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Staphylococcus Aureus Bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Staphylococcus Aureus Bronchitis:

Cite this brief

Drug Landscape (2026). Staphylococcus Aureus Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staphylococcus-aureus-bronchitis. Accessed 2026-06-10.

Staphylococcus Aureus Bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing